Cue Biopharma(CUE)
$18.76+-1.38 (+0.16%)
CUE
Cue Biopharma financials statements
$18.76
At close:+-1.38 (+0.16%)
Want to see CUE full AI Analyst Report?
Cue Biopharma (CUE) Ratios
671 Followers
Cue Biopharma Ratios
CUE's free cash flow for Q2 2026 was $-29.00M. For the 2026 fiscal year, CUE's free cash flow was increased by $0.00 and operating cash flow was $-29.00M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Mar 25 | Mar 24 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.74 | 1.84 | 3.01 | 6.68 | 5.35 |
| Quick Ratio | 2.74 | 1.84 | 3.01 | 6.68 | 5.35 |
| Cash Ratio | 2.01 | 1.64 | 2.84 | 4.47 | 5.03 |
| Solvency Ratio | -1.63 | -2.61 | -1.93 | -2.00 | -2.57 |
| Operating Cash Flow Ratio | -1.61 | -2.65 | -2.34 | -3.62 | -3.04 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -8.38 | -10.08 | -21.30 | -19.73 |
| Net Current Asset Value | $ 21.20M | $ 10.45M | $ 27.01M | $ 51.59M | $ 50.56M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.10 | 0.28 | 0.24 | 0.21 | 0.14 |
| Debt-to-Equity Ratio | 0.16 | 0.51 | 0.40 | 0.29 | 0.18 |
| Debt-to-Capital Ratio | 0.14 | 0.34 | 0.28 | 0.23 | 0.16 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.10 | 0.11 | 0.00 |
| Financial Leverage Ratio | 1.60 | 1.84 | 1.66 | 1.39 | 1.27 |
| Debt Service Coverage Ratio | -70.83 | -7.32 | -8.84 | -18.86 | -23.34 |
| Interest Coverage Ratio | -74.29 | -52.14 | -41.89 | -74.56 | 0.00 |
| Debt to Market Cap | 0.00 | 0.07 | 0.07 | 0.10 | 0.01 |
| Interest Debt Per Share | 1.44 | 5.15 | 0.35 | 0.56 | 0.38 |
| Net Debt to EBITDA | 0.93 | 0.36 | 0.73 | 0.64 | 1.15 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 100.00% | -593.93% | 100.00% | 111.90% |
| EBIT Margin | -93.73% | -429.40% | -901.42% | -4200.56% | -292.25% |
| EBITDA Margin | -90.25% | -404.09% | -838.83% | -4055.50% | -304.15% |
| Operating Profit Margin | -96.56% | -446.86% | -949.89% | -4275.10% | -292.56% |
| Pretax Profit Margin | -95.03% | -437.97% | -924.10% | -4257.83% | -292.25% |
| Net Profit Margin | -96.85% | -437.97% | -924.10% | -4257.83% | -295.56% |
| Continuous Operations Profit Margin | -96.85% | -437.97% | -924.10% | -4257.83% | -295.56% |
| Net Income Per EBT | 101.92% | 100.00% | 100.00% | 100.00% | 101.13% |
| EBT Per EBIT | 98.42% | 98.01% | 97.28% | 99.60% | 99.89% |
| Return on Assets (ROA) | -63.02% | -126.35% | -82.45% | -58.07% | -52.95% |
| Return on Equity (ROE) | -100.64% | -232.44% | -136.80% | -80.71% | -67.43% |
| Return on Capital Employed (ROCE) | -92.35% | -224.30% | -117.32% | -66.75% | -61.90% |
| Return on Invested Capital (ROIC) | -86.59% | -157.35% | -100.71% | -62.62% | -56.39% |
| Return on Tangible Assets | -63.02% | -126.35% | -82.45% | -58.07% | -52.95% |
| Earnings Yield | -91.97% | -66.25% | -42.00% | -52.18% | -12.48% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.69 | 9.83 | 3.23 | 21.84 | 4.75 |
| Payables Turnover | 0.00 | 0.00 | 10.88 | 0.00 | -0.69 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 6.37 | 1.92 | 0.77 | 0.12 | 1.25 |
| Asset Turnover | 0.65 | 0.29 | 0.09 | 0.01 | 0.18 |
| Working Capital Turnover Ratio | 1.57 | 0.41 | 0.11 | 0.02 | 0.24 |
| Cash Conversion Cycle | 98.94 | 37.14 | 79.35 | 16.71 | 608.61 |
| Days of Sales Outstanding | 98.94 | 37.14 | 112.89 | 16.71 | 76.77 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 33.54 | 0.00 | -531.84 |
| Operating Cycle | 98.94 | 37.14 | 112.89 | 16.71 | 76.77 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -6.87 | -19.35 | -0.87 | -1.17 | -1.24 |
| Free Cash Flow Per Share | -6.92 | -19.38 | -0.87 | -1.18 | -1.27 |
| Dividend Paid and CapEx Coverage Ratio | -122.53 | -550.44 | 0.00 | -244.48 | -42.54 |
| Capital Expenditure Coverage Ratio | -122.53 | -550.44 | 0.00 | -244.48 | -42.54 |
| Operating Cash Flow Coverage Ratio | -5.17 | -4.09 | -2.72 | -2.16 | -3.23 |
| Operating Cash Flow to Sales Ratio | -0.79 | -3.91 | -7.28 | -33.58 | -2.60 |
| Free Cash Flow Yield | -75.59% | -59.28% | -33.08% | -41.32% | -11.23% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.09 | -1.51 | -2.38 | -1.92 | -8.01 |
| Price-to-Sales (P/S) Ratio | 1.05 | 6.61 | 22.00 | 81.61 | 23.68 |
| Price-to-Book (P/B) Ratio | 1.09 | 3.51 | 3.26 | 1.55 | 5.40 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.32 | -1.69 | -3.02 | -2.42 | -8.90 |
| Price-to-Operating Cash Flow Ratio | -1.33 | -1.69 | -3.02 | -2.43 | -9.11 |
| Price-to-Earnings Growth (PEG) Ratio | 0.02 | 0.04 | 0.09 | -0.34 | 0.83 |
| Enterprise Value Multiple | -0.24 | -1.27 | -1.89 | -1.37 | -6.63 |
| Enterprise Value | 5.99M | 47.81M | 86.97M | 69.30M | 301.49M |
| EV to EBITDA | -0.24 | -1.27 | -1.89 | -1.37 | -6.63 |
| EV to Sales | 0.22 | 5.15 | 15.84 | 55.66 | 20.18 |
| EV to Free Cash Flow | -0.27 | -1.31 | -2.18 | -1.65 | -7.58 |
| EV to Operating Cash Flow | -0.28 | -1.32 | -2.18 | -1.66 | -7.76 |
| Tangible Book Value Per Share | 8.37 | 9.32 | 0.81 | 1.84 | 2.09 |
| Shareholders’ Equity Per Share | 8.37 | 9.32 | 0.81 | 1.84 | 2.09 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.02 | 0.00 | 0.00 | 0.00 | -0.01 |
| Revenue Per Share | 8.70 | 4.95 | 0.12 | 0.03 | 0.48 |
| Net Income Per Share | -8.42 | -21.66 | -1.11 | -1.49 | -1.41 |
| Tax Burden | 1.02 | 1.00 | 1.00 | 1.00 | 1.01 |
| Interest Burden | 1.01 | 1.02 | 1.03 | 1.01 | 1.00 |
| Research & Development to Revenue | 1.37 | 3.91 | 7.43 | 30.99 | 2.77 |
| SG&A to Revenue | 0.59 | 1.57 | 3.04 | 12.99 | 1.16 |
| Stock-Based Compensation to Revenue | 0.17 | 0.74 | 1.49 | 7.63 | 0.77 |
| Income Quality | 0.82 | 0.89 | 0.79 | 0.79 | 0.88 |
Currency in USD
